
maintenance (Flamm et al., Obstet. Gynecol., 70, 1987, 70 – 12), wound healing and infection, mastitis and placenta delivery, and osteoporosis. Additionally, oxytocin agonists may be useful for the diagnosis of both cancer and placental insufficiency.

Furthermore, the Articles "Intranasal Oxytocin blocks alcohol withdrawal in human subjects" (Alcohol Clin Exp Res, Vol, No. 2012) and "Breaking the loop: Oxytocin as a potential treatment for drug addiction" (Hormones and Behavior, 61, 2012 , 331- 339) propose to treat alcohol withdrawal and drug addiction with a oxytocin agonist.

Oxytocin and its receptors exists in areas of the brain implicated in the symptoms of schizophrenia, such as the nucleus accumbens and the hippocampus. The oxytocin receptor agonists may be used for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, Alzheimer's disease, psychiatric disorders, memory loss and metabolic diseases (WO2012/016229).

Objects of the embodiments disclosed herein are novel compounds of formula I and the use of compounds of formula I and their pharmaceutically acceptable salts for the treatment of CNS diseases related to the oxytocin receptor, which diseases are autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal,drug addiction and for the treatment of Prader-Willi Syndrom.

In one aspect, there is provided a compound of formula



I

wherein

R^1 is hydrogen, C_{1-7}-alkyl, -CH_2-C_{3-6}-cycloalkyl or C_{3-6}-cycloalkyl;

R^2 is hydrogen, C_{1-7}-alkyl, C_{1-7}-alkyl substituted by hydroxy or

R^1 and R^2 may form together with the N and C atom to which they are attached a pyrrolidine ring optionally substituted by one or two F-atoms or by hydroxy, or may form an azetidine or a piperidine ring;

R^3 is hydrogen, C_{1-7}-alkyl, C_{1-7}-alkyl substituted by hydroxy, $-(CH_2)_oNH_2$, benzyl optionally substituted by hydroxy, phenyl, $-CH_2-C_{3-6}$-cycloalkyl or C_{3-6}-cycloalkyl;

$R^{3'}$ is hydrogen or C_{1-7}-alkyl;

n is 1;

m is 0 or 1;

o is 1 to 4;

or a pharmaceutically acceptable acid addition salt, a racemic mixture or its corresponding enantiomer and/or optical isomers thereof.

Further objects are the preparation of novel compounds of formula I and medicaments, containing them.

The present disclosure may provide selective, efficacious compounds, providing alternatives and/or improvements in the treatment of certain CNS diseases including autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrom.

In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a pharmaceutical acceptable carrier and/or adjuvant.


In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a pharmaceutical acceptable carrier and/or adjuvant for use in the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrom.

In another aspect, there is provided a compound as defined herein for use as therapeutic active substances.

In another aspect, there is provided a compound as defined herein for use as therapeutic active substances in the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader Willi Syndrom.

Claims

1. A compound of formula



I

wherein

R^1 is hydrogen, C_{1-7}-alkyl, $-CH_2-C_{3-6}$-cycloalkyl or C_{3-6}-cycloalkyl;

R^2 is hydrogen, C_{1-7}-alkyl, C_{1-7}-alkyl substituted by hydroxy or

R^1 and R^2 may form together with the N and C atom to which they are attached a pyrrolidine ring optionally substituted by one or two F-atoms or by hydroxy, or may form an azetidine or a piperidine ring;

R^3 is hydrogen, C_{1-7}-alkyl, C_{1-7}-alkyl substituted by hydroxy, $-(CH_2)_oNH_2$, benzyl optionally substituted by hydroxy, phenyl, $-CH_2-C_{3-6}$-cycloalkyl or C_{3-6}-cycloalkyl;

$R^{3'}$ is hydrogen or C_{1-7}-alkyl;

n is 1;

m is 0 or 1;

o is 1 to 4;

or a pharmaceutically acceptable acid addition salt, a racemic mixture or its corresponding enantiomer and/or optical isomers thereof.

2. A compound of formula I according to claim 1, wherein m is 1.

3.A compound of formula I according to any one of claims 1 or 2, wherein R^1 is hydrogen, C_{1-7}-alkyl, -CH_2-C_{3-6}-cycloalkyl or C_{3-6}-cycloalkyl and R^2 is hydrogen, C_{1-7}-alkyl, C_{1-7}-alkyl substituted by hydroxy and the other definitions are as described in claim 1.

4. A compound of formula I according to any one of claims 1 or 2, wherein R^1 and R^2 may form together with the N and C atom to which they are attached a pyrrolidine ring optionally substituted by one or two F-atoms or by hydroxy, or may form an azetidine or a piperidine ring, and the other definitions are as described in claim 1.

5. A compound of formula I accoccording to claim 1, wherein the compounds are

